Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00009997 · ClinicalTrials.gov registry record · Phase 1
Trastuzumab and Chemotherapy Followed by Surgery and Combination Chemotherapy in Treating Women With Locally Advanced Breast Cancer
A Phase 1 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00009997: Completed Phase 1 study, sponsored by NYU Langone Health.
NCT00009997 is a Phase 1 study that has completed, run by NYU Langone Health. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00009997, a Phase 1 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining monoclonal antibody therapy with combination chemotherapy may be an effective treatment for locally advanced breast cancer. PURPOSE: Phase I trial to study the effectiveness of trastuzumab plus paclitaxel followed by surgery and combination chemotherapy in treating women who have locally advanced breast cancer.
Interventions
- DRUG cyclophosphamide
- DRUG paclitaxel
- BIOLOGICAL trastuzumab
- DRUG doxorubicin hydrochloride
- DRUG tamoxifen citrate
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-03 |
| Phase | Phase 1 |
What the finished NCT00009997 record still lists
NCT00009997 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00009997 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00009997 about?
NCT00009997 is a clinical study titled "Trastuzumab and Chemotherapy Followed by Surgery and Combination Chemotherapy in Treating Women With Locally Advanced Breast Cancer". RATIONALE: Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining monoclonal...
What is the current status of trial NCT00009997?
This trial is currently completed. It is a Phase 1 study. The study started on 1999-03.
What interventions are being tested in trial NCT00009997?
The interventions under investigation include: cyclophosphamide (DRUG), paclitaxel (DRUG), trastuzumab (BIOLOGICAL), doxorubicin hydrochloride (DRUG), tamoxifen citrate (DRUG).
Who is sponsoring clinical trial NCT00009997?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia